Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis
Abstract Background The efficacy of breast reconstruction for patients with N2‐3M0 stage female breast cancer (FBC) remained unclear due to the lack of randomized clinical trials. This retrospective study aimed to explore the efficacy of breast reconstruction for patients with N2‐3M0 stage FBC. Meth...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6579 |
| _version_ | 1826575845701976064 |
|---|---|
| author | Yuting Zhao Lutong Yan Shouyu Li Zejian Yang Na Chai Pei Qiu Huimin Zhang Jianjun He Can Zhou |
| author_facet | Yuting Zhao Lutong Yan Shouyu Li Zejian Yang Na Chai Pei Qiu Huimin Zhang Jianjun He Can Zhou |
| author_sort | Yuting Zhao |
| collection | DOAJ |
| description | Abstract Background The efficacy of breast reconstruction for patients with N2‐3M0 stage female breast cancer (FBC) remained unclear due to the lack of randomized clinical trials. This retrospective study aimed to explore the efficacy of breast reconstruction for patients with N2‐3M0 stage FBC. Methods Two thousand five hundred forty‐five subjects with FBC staged by N2‐3M0 from 2010 to 2016 were retrieved from the Surveillance, Epidemiology, and End Results database. Generalized boosted model (GBM) and propensity score matching (PSM) analyses and multivariable Cox analyses were employed to assess the clinical prognostic effect of postmastectomy reconstruction for patients with N2‐3M0 stage FBC in breast cancer‐specific survival (BCSS). Results Totally, 1784 candidates underwent mastectomy alone (mastectomy group), and 761 candidates underwent postmastectomy reconstruction (PMbR group), with 418 breast‐specific deaths after a median follow‐up time of 57 months (ranging from 7 to 227 months). BCSS in the mastectomy group showed no statistical difference from that in the PMbR group in the PSM cohort (HR = 0.93, 95% CI: 0.70–1.25, p = 0.400) and GBM cohort (HR = 0.75, 95% CI: 0.56–1.01, p = 0.057). In the multivariate analyses, there was no difference in the effect of PMbR and mastectomy on BCSS in the original cohort (HR = 0.85, 95% CI: 0.66–1.09, p = 0.197), PSM cohort (HR = 0.86, 95% CI: 0.64–1.15, p = 0.310), and GBM cohort (HR = 0.84, 95% CI: 0.61–1.17, p = 0.298). Triple‐negative breast cancer (TNBC) was a detrimental factor affecting BCSS for patients in the PMbR group. Conclusions Our study demonstrated that PMbR is an oncologically safe surgical treatment and can be widely recommended in clinics for females with non‐TNBC staged by T0‐3N2‐3M0. |
| first_indexed | 2024-03-11T10:14:08Z |
| format | Article |
| id | doaj.art-ca8c56e70b0b4013bcf077fde140dac3 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2025-03-14T13:21:10Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-ca8c56e70b0b4013bcf077fde140dac32025-02-28T11:43:27ZengWileyCancer Medicine2045-76342023-10-011220202872029810.1002/cam4.6579Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysisYuting Zhao0Lutong Yan1Shouyu Li2Zejian Yang3Na Chai4Pei Qiu5Huimin Zhang6Jianjun He7Can Zhou8Department of Gynecologic Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Pediatric surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaDepartment of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an ChinaAbstract Background The efficacy of breast reconstruction for patients with N2‐3M0 stage female breast cancer (FBC) remained unclear due to the lack of randomized clinical trials. This retrospective study aimed to explore the efficacy of breast reconstruction for patients with N2‐3M0 stage FBC. Methods Two thousand five hundred forty‐five subjects with FBC staged by N2‐3M0 from 2010 to 2016 were retrieved from the Surveillance, Epidemiology, and End Results database. Generalized boosted model (GBM) and propensity score matching (PSM) analyses and multivariable Cox analyses were employed to assess the clinical prognostic effect of postmastectomy reconstruction for patients with N2‐3M0 stage FBC in breast cancer‐specific survival (BCSS). Results Totally, 1784 candidates underwent mastectomy alone (mastectomy group), and 761 candidates underwent postmastectomy reconstruction (PMbR group), with 418 breast‐specific deaths after a median follow‐up time of 57 months (ranging from 7 to 227 months). BCSS in the mastectomy group showed no statistical difference from that in the PMbR group in the PSM cohort (HR = 0.93, 95% CI: 0.70–1.25, p = 0.400) and GBM cohort (HR = 0.75, 95% CI: 0.56–1.01, p = 0.057). In the multivariate analyses, there was no difference in the effect of PMbR and mastectomy on BCSS in the original cohort (HR = 0.85, 95% CI: 0.66–1.09, p = 0.197), PSM cohort (HR = 0.86, 95% CI: 0.64–1.15, p = 0.310), and GBM cohort (HR = 0.84, 95% CI: 0.61–1.17, p = 0.298). Triple‐negative breast cancer (TNBC) was a detrimental factor affecting BCSS for patients in the PMbR group. Conclusions Our study demonstrated that PMbR is an oncologically safe surgical treatment and can be widely recommended in clinics for females with non‐TNBC staged by T0‐3N2‐3M0.https://doi.org/10.1002/cam4.6579breast cancerbreast cancer‐specific survivalbreast reconstructiongeneralized boosted modelpropensity score matchingSEER |
| spellingShingle | Yuting Zhao Lutong Yan Shouyu Li Zejian Yang Na Chai Pei Qiu Huimin Zhang Jianjun He Can Zhou Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis Cancer Medicine breast cancer breast cancer‐specific survival breast reconstruction generalized boosted model propensity score matching SEER |
| title | Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis |
| title_full | Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis |
| title_fullStr | Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis |
| title_full_unstemmed | Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis |
| title_short | Efficacy of breast reconstruction for N2‐3M0 stage female breast cancer on breast cancer‐specific survival: A population‐based propensity score analysis |
| title_sort | efficacy of breast reconstruction for n2 3m0 stage female breast cancer on breast cancer specific survival a population based propensity score analysis |
| topic | breast cancer breast cancer‐specific survival breast reconstruction generalized boosted model propensity score matching SEER |
| url | https://doi.org/10.1002/cam4.6579 |
| work_keys_str_mv | AT yutingzhao efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT lutongyan efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT shouyuli efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT zejianyang efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT nachai efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT peiqiu efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT huiminzhang efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT jianjunhe efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis AT canzhou efficacyofbreastreconstructionforn23m0stagefemalebreastcanceronbreastcancerspecificsurvivalapopulationbasedpropensityscoreanalysis |